Monte Rosa Therapeutics (NASDAQ:GLUE) Upgraded to Strong-Buy at HC Wainwright

HC Wainwright upgraded shares of Monte Rosa Therapeutics (NASDAQ:GLUE) to a strong-buy rating in a report published on Thursday,Zacks reports.

Several other equities research analysts have also issued reports on the stock. JPMorgan Chase & Co. lowered their target price on shares of Monte Rosa Therapeutics from $31.00 to $27.00 and set an “overweight” rating for the company in a report on Friday, August 7th. Weiss Ratings downgraded shares of Monte Rosa Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a report on Tuesday, August 11th. Wells Fargo & Company decreased their price objective on shares of Monte Rosa Therapeutics from $29.00 to $27.00 and set an “overweight” rating for the company in a research note on Friday, August 7th. Jefferies Financial Group reiterated a “buy” rating on shares of Monte Rosa Therapeutics in a report on Monday, July 27th. Finally, TD Cowen upgraded Monte Rosa Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $28.00.

Monte Rosa Therapeutics Price Performance

Shares of NASDAQ GLUE opened at $11.26 on Thursday. Monte Rosa Therapeutics has a 1-year low of $7.24 and a 1-year high of $25.77. The business’s 50 day moving average is $14.88 and its two-hundred day moving average is $17.76. The stock has a market capitalization of $960.59 million, a P/E ratio of -6.40 and a beta of 1.37.

Monte Rosa Therapeutics (NASDAQ:GLUE) last released its earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The company had revenue of $8.97 million for the quarter, compared to the consensus estimate of $12.91 million. Monte Rosa Therapeutics had a negative net margin of 560.85% and a negative return on equity of 43.31%. As a group, equities research analysts anticipate that Monte Rosa Therapeutics will post -1.04 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Sharon Townson sold 6,000 shares of the business’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $23.31, for a total value of $139,860.00. Following the completion of the sale, the insider owned 67,845 shares in the company, valued at approximately $1,581,466.95. The trade was a 8.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 6.40% of the company’s stock.

Hedge Funds Weigh In On Monte Rosa Therapeutics

Several institutional investors have recently bought and sold shares of GLUE. Allworth Financial LP purchased a new position in shares of Monte Rosa Therapeutics in the 2nd quarter valued at $30,000. Seven Fleet Capital Management LP purchased a new position in Monte Rosa Therapeutics in the fourth quarter valued at about $63,000. E Fund Management Co. Ltd. bought a new position in Monte Rosa Therapeutics in the second quarter worth about $200,000. AlphaCentric Advisors LLC bought a new position in Monte Rosa Therapeutics in the first quarter worth about $207,000. Finally, AXQ Capital LP purchased a new stake in shares of Monte Rosa Therapeutics during the fourth quarter valued at about $215,000. 79.96% of the stock is owned by hedge funds and other institutional investors.

Monte Rosa Therapeutics News Summary

Here are the key news stories impacting Monte Rosa Therapeutics this week:

• Positive Sentiment: Positive Phase 1 results: MRT-8102 produced robust and sustained NEK7 degradation at all tested once-daily doses. In obese participants with elevated cardiovascular risk, several disease-related biomarkers—including HMGB1, calprotectin, S100A12, serum amyloid A and IL-1β—fell to levels comparable with those observed in healthy volunteers. Monte Rosa Announces Positive MRT-8102 GFORCE-1 Results
• Positive Sentiment: Favorable safety profile: Four weeks of treatment and four weeks of follow-up produced no serious adverse events, adverse-event rates comparable with placebo, and no evidence of increased infection risk. Monte Rosa plans Phase 2 studies in coronary artery disease, gout and hidradenitis suppurativa. Monte Rosa Plans Mid-Stage Trials for MRT-8102
• Positive Sentiment: New analyst support: HC Wainwright initiated coverage with a Buy rating and a $25 price target, providing additional external validation of Monte Rosa’s molecular-glue platform and development pipeline. HC Wainwright Initiates Coverage
• Neutral Sentiment: The data measure biomarker normalization rather than clinical cardiovascular outcomes. Investors will likely focus on whether Phase 2 trials confirm efficacy, durability and safety in larger patient populations.
• Negative Sentiment: The weaker share performance suggests some investors may be taking profits or adopting a more cautious view after the initial data reaction, particularly because MRT-8102 remains an early-stage asset and Phase 2 execution will require additional time and funding.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins. The company uses its proprietary molecular glue degrader platform to identify small molecules that recruit targeted proteins to the cell’s natural protein-disposal machinery, potentially addressing proteins that have been difficult to treat with conventional drugs.

Monte Rosa’s pipeline is centered primarily on autoimmune and inflammatory diseases, as well as other serious conditions.